IPP Bureau
Mawi DNA Technologies launches NextSWAB for Covid-19 test results
By IPP Bureau - May 12, 2022
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
Boehringer Ingelheim’s signal analytics technology acquired by ArisGlobal
By IPP Bureau - May 12, 2022
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
GenNext Technologies introduces protein footprinting products to Japan through Kiko Tech
By IPP Bureau - May 12, 2022
GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation Protein Footprinting Systems.
OvaCis rapid test to detect ovarian cancer gets CE mark
By IPP Bureau - May 12, 2022
Revolutionary ovarian cancer rapid test available Q4 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
By IPP Bureau - May 12, 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
By IPP Bureau - May 12, 2022
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Philips expands manufacturing and research facility in Pune, Maharashtra
By IPP Bureau - May 12, 2022
The company exports mobile surgery equipment to over 100 countries from Pune
Emmes launches Advantage eClinical as a standalone cloud-native clinical technology platform
By IPP Bureau - May 12, 2022
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
New two-year Deucravacitinib data show promising results for severe plaque psoriasis
By IPP Bureau - May 12, 2022
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
By IPP Bureau - May 12, 2022
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Ajanta Pharma - Stellar show in its branded generics: Anand Rathi
By IPP Bureau - May 12, 2022
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
‘One Step’ portal to provide information on medical tourism: Dr Mansukh Mandaviya
By IPP Bureau - May 12, 2022
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
Dr. Agarwal's Health Care raises over Rs 1,000 crore from TPG Growth and Temasek
By IPP Bureau - May 11, 2022
The company also raised Rs 270 crore investment from Temasek in 2019
Aurobindo Pharma Ltd gets 6 observations from USFDA for Unit VII
By IPP Bureau - May 11, 2022
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022
By IPP Bureau - May 11, 2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
